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Targeted delivery of etoposide to osteosarcoma cells using
poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles
1

1,2

1

3

1,

Esma ALP , Tamer ÇIRAK , Murat DEMİRBİLEK , Mustafa TÜRK , Eylem GÜVEN *
1
Nanotechnology and Nanomedicine Division, Hacettepe University, Ankara, Turkey
2
Alternative Energy Sources Division, Vocational School of Technical Sciences, Aksaray University, Aksaray, Turkey
3
Department of Bioengineering, Faculty of Engineering, Kırıkkale University, Kırıkkale, Turkey
Received: 09.12.2016

Accepted/Published Online: 11.02.2017

Final Version: 10.11.2017

Abstract: Folic acid (FA)-functionalized poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles were prepared to
enhance the delivery efficiency of the anticancer drug etoposide for the clinical treatment of osteosarcoma. PHBV nanoparticles were
synthesized by emulsification/solvent evaporation technique and obtained in the size range of 200–250 nm and zeta potential range of
–21 and –27 mV. Encapsulation efficiency and in vitro drug release were studied. The cytotoxic, apoptotic, and necrotic effects of PHBV
nanoparticles were also investigated using Saos-2 osteosarcoma cells. The results obtained in this study demonstrate that etoposideloaded and FA-functionalized PHBV nanoparticles can be successfully used for targeted treatment of osteosarcoma.
Key words: PHBV nanoparticle, folate targeting, etoposide, targeted drug delivery, osteosarcoma

1. Introduction
Osteosarcoma (OS), or osteogenic sarcoma, is the most
common primary bone tumor in children and adolescents,
accounting for 5% of all pediatric malignancies. It is
a high-grade neoplasm with rapid growth and early
metastasis, which typically is pulmonary. Current major
OS therapy options include combinations of surgery and
chemotherapy. Various chemotherapeutic agents, such as
doxorubicin, methotrexate, cyclophosphamide, etoposide,
and cisplatin, are commonly used, either alone or in
combination (Wittig et al., 2002). Although the 5-year
survival rate is 15% to 20% for patients with localized
osteosarcoma with surgery alone, it increases dramatically
to approximately 70% in combination with chemotherapy.
However, the eventual development of multidrug resistance
to multiple types of chemotherapeutic agents hampers the
efficacy of chemotherapy. It is estimated that less than 30%
of patients with recurrent disease will be cured (Schwartz
et al., 2007). Therefore, more effective therapeutic agents
with higher specificity and lower toxicity are needed to
overcome the dose-limiting side effects of conventional
chemotherapeutic agents and therapeutic failure due to
multidrug resistant tumor cells.
An effective approach to improving the therapeutic
indices of anticancer agents is the development of targeted
drug delivery systems utilizing nanotechnological
* Correspondence: eylemoz@hacettepe.edu.tr

strategies. Nanoparticles have the potential to deliver
chemotherapeutic agents to targeted cells and make
therapeutic delivery procedures more effective, more
precise, and less harmful to healthy tissues (Jabir et al.,
2012). Polymeric nanoparticles have attracted much
attention as drug delivery systems based on their ease of
preparation and ability to tailor their properties for the
design of suitable targeted drug delivery systems with
required characteristics (Parveen and Sahoo, 2008). To
improve nanoparticular drug delivery, active targeting
is widely used. In active targeting, nanoparticles are
chemically modified with different ligands that precisely
recognize and specifically interact with receptors on
targeted cells (Yu et al., 2012).
Folate receptors are highly specific tumor markers
overexpressed in many human cancer types, including
ovarian cancer, choriocarcinomas, uterine sarcomas,
and osteocarcinomas (Vasir and Labhasetwar, 2005).
They have gained considerable attention for targeted
drug delivery. Folic acid has been frequently used to
specifically target attached chemotherapeutic agents to
tumor cells that overexpress folate receptors (Low and
Kularatne, 2009). Functionalization of nanoparticles with
folic acid significantly enhances the internalization and
binding affinity of the nanoparticles toward folate receptor
overexpressed cells.
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Etoposide, a derivative of podophyllotoxin, is
an antineoplastic drug used to treat various human
cancer types, such as lung cancer, lymphomas, Ewing’s
sarcoma, ovarian cancer, and osteosarcoma (Hande,
1998). Etoposide, the most frequently prescribed
chemotherapeutic agent currently used for the treatment
of human cancers, induces DNA damage by inhibition of
topoisomerase II. However, etoposide has poor solubility
in water, limited chemical and physical stability, and side
effects on patients. In order to eliminate these problems,
particulate drug delivery systems have been used
(Dhanaraju et al., 2010; Zhang et al., 2011).
Polyhydroxyalkanoates (PHAs), synthesized by a
variety of microorganisms, are a class of naturally occurring
biodegradable and biocompatible polyesters. They have
gained significant attention as drug delivery materials
due to their promising physicochemical and mechanical
properties. Poly(3-hydroxybutyrate) (PHB) is the first
and the most extensively studied member of the PHA
family. However, PHB has brittleness and low mechanical
strength, which makes it restricted for these applications.
On the other hand, the poor low-impact strength of PHB
is eliminated by incorporating hydroxyvalerate monomers
into the polymer chain to produce polyhydroxybutyrateco-valerate (PHBV). The addition of polyhydroxyvalerate
(PHV) to the PHB polymer chain in varying ratios reduces
crystallinity and makes it more flexible and more easily
processable than PHB itself (Gassner and Owen, 1996).
In the present study, we developed PHBV nanoparticles
for the targeted delivery of etoposide to osteosarcoma
cells. Folic acid was used as the targeting ligand to take
advantage of folate-receptor–mediated endocytosis.
Obtained nanoparticles were characterized using zeta
sizer, zeta potential, FT–IR, and scanning electron
microscopy. In vitro etoposide release and encapsulation
efficiency were investigated. Furthermore, the delivery
system was evaluated for cytotoxicity using an MTT-based
assay. Apoptosis and necrosis indices were also evaluated.
The cytotoxic, apoptotic, and necrotic effects of PHBV
nanoparticles were investigated using the folate-receptor–
overexpressing Saos-2 osteosarcoma cells.
2. Materials and methods
PHBV (8% 3-hydroxyvalerate, Mw = 150,000),
3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium
bromide, folic acid, 1-ethyl-3-(3-dimethyl-aminopropyl)
carbodiimide (EDAC), and MES were purchased from
Sigma Aldrich (St. Louis, MO, USA). Etoposide was
purchased from Ebewe Pharma (Unterach, Austria).
Chloroform, ethyl alcohol, and Tween 80 were purchased
from Merck (Darmstadt, Germany). Trypsin-EDTA,
D-MEM/F-12, FCS, DMSO, penicillin–streptomycin,
RPMI 1640 medium, and L-glutamine were purchased
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from Biological Industries (Beit-Haemek, Israel). Hoechst
33342 and propidium iodide were purchased from Serva
(Abu-Gosh, Israel). Annexin-V-FLUOS was purchased
from Roche (Indianapolis, IN, USA).
2.1. Preparation of PHBV nanoparticles
PHBV nanoparticles were prepared by an emulsification/
solvent evaporation technique adapted from previously
described methods (Vilos et al., 2013). Briefly, 10 mg of
PHBV was dissolved in 10 mL of chloroform to obtain 0.1%
(w/v) organic phase. The organic phase was injected into
an aqueous phase containing 6% (w/v) Tween 80/distilled
water with a syringe in a high-speed homogenizer at 24,000
rpm (Ultra-Turrax, T18 basic, IKA; Staufen im Breisgau,
Germany) in an inert nitrogen-filled environment.
The organic solvent was allowed to volatilize while the
nanoparticles formed under continuous mechanical
stirring at room temperature for 2 h. PHBV nanoparticles
were collected following centrifugation at 12,000 rpm
for 30 min and washed three times with distilled water.
Drug-loaded nanoparticles were prepared using the same
method, except that PHBV and etoposide were dissolved
in chloroform at different polymer/drug ratios (w/w) (1/1,
1/0.5, 1/0.25) prior to emulsification (Table 1). Obtained
nanoparticles were lyophilized using a freeze dryer.
2.2. Fabrication of folic-acid–conjugated PHBV
nanoparticles
Folic-acid–conjugated PHBV nanoparticles were
synthesized by carbodiimide method (Kilicay et al., 2011).
Folic acid was attached to PHBV nanoparticles through
the formation of an amide linkage between the carboxyl
group of PHBV and the amine group of folic acid using
EDAC. Briefly, 1.0 mg/mL folic acid solution was prepared
in 1.0 mL of water by adjusting the pH to weak alkaline.
Folate-attached PHBV nanoparticles were obtained by
the addition of folate solution into the activated 10.0
mL of PHBV nanoparticle suspension (1.0 mg/mL)
corresponding to a PHBV:EDAC weight ratio of 1:1 and
2 h of activation time. The mixture was stirred at room
temperature for 24 h. The nanoparticle suspension was
centrifuged at 12,000 rpm for 30 min and the supernatants
were stored for further analysis. Nanoparticles were
washed with distilled water and freeze-dried to get the
nanoparticle powder. The quantity of unconjugated folic
acid remaining in the supernatant was determined using
a UV–Vis spectrophotometer (NanoDrop ND-1000,
Thermo Scientific; Waltham, MA, USA) by measuring the
UV absorbance at λ = 280 nm.
2.3. Characterization of PHBV nanoparticles
SEM (ESEM, FEI Quanta; Houston, TX, USA) was used
to examine the nanoparticle morphologies. FTIR analysis
was carried out for the structural characterization of
nanoparticles (Shimadzu, DR8101; Kyoto, Japan). All size
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and size distribution parameters were measured according
to dynamic light scattering measurements (DLS) using a
Zetasizer nanoparticle analyzer (Malvern Instruments,
Model 3000 HSA; Malvern, UK). The particle size and
polydispersity index (PdI) for each sample were measured
twice and the average value was reported. The zeta potential
values were determined using a Zetasizer nanoparticle
analyzer.
2.4. Determination of entrapment efficiency
Nanoparticles at different initial polymer/drug ratios (w/w)
(i.e. 1/1, 1/0.5, and 1/0.25) were dissolved in chloroform
for the extraction of the drug from nanoparticles and the
amount of drug in the solution was measured using a UV–
Vis spectrophotometer (NanoDrop ND-1000, Thermo
Scientific) at a wavelength of 284 nm. The entrapment
efficiency (EE) was then calculated using Eq. (1):
EE % =

weight of drug in nanoparticles
× 100%
initial weight of drug used in the formulation

2.5. In vitro etoposide release studies
The in vitro release studies of PHBV nanoparticles were
carried out at 37 °C in phosphate-buffered saline (PBS,
pH 7.4). Typically, 5 mL of PBS was added into two
compartments separated by a dialysis membrane, and 50
mg of PHBV nanoparticles at different initial polymer/
drug ratios (w/w) (1/1, 1/0.5, 1/0.25) were added to one
of the compartments. The entire system was kept at 37 °C
by gentle shaking in a water bath. Samples (0.2 mL) were
removed from the receptor compartment at predetermined
time intervals and replaced with the same volume of
fresh buffer. The amount of free etoposide released
from the nanoparticles was measured using a UV–Vis
spectrophotometer at a wavelength of 284 nm (NanoDrop
ND-1000, Thermo Scientific). Experiments were carried
out in triplicate.
2.6. Cytotoxicity assay
The cellular toxicity of blank PHBV nanoparticles as well as
nontargeted and folic-acid–targeted PHBV nanoparticles
at different initial polymer/drug ratios (1/1, 1/0.5, and
1/0.25) and nanoparticle concentrations (5, 10, 25, and 50
µg/mL) were determined by using the Saos-2 osteosarcoma
cell line. Free etoposide at various concentrations (5,
10, 25, and 50 µg/mL) was also tested. The cells were
cultured in DMEM/F-12 medium supplemented with
10% FBS and 1% penicillin–streptomycin. A total of 5 ×
103 cells were seeded in 96-well plates. After incubation
at 37 °C in a 5% CO2-humidified incubator overnight, the
medium was discarded and plates were washed with buffer
solution. Subsequently cells were treated with samples of
increasing concentrations (5, 10, 25, and 50 µg/mL) for
24 h and 48 h. The cell viabilities at given time intervals
were measured using MTT (3-(4,5-dimethylthiazole-

2-yl)-2,5-diphenyl tetrazolium) assay, which monitors
the mitochondrial metabolism of cells as an indicator of
viability (van Meerloo et al., 2011). Briefly, 100 µL of MTT
reagent (5.0 mg/mL, diluted with RPMI 1640 without
phenol red, filtered through a 0.22-µm filter) was added to
each well after the cells were washed with buffer solution
to remove noninternalized nanoparticles. After 4 h of
incubation (37 °C and 5% CO2), the medium was removed
and 100 µL of isopropanol with 0.04 N HCl was added to
each well to ensure solubilization of formazan crystals by
shaking at 240 rpm for 10 min. Finally, the absorbance was
determined using an ELISA plate reader (ASYS Expert Plus
ELISA reader, Biochrom Ltd.; Cambourne, UK) at 570 nm.
Cytotoxicity studies were performed in triplicate and the
data were represented as mean ± standard deviation (SD).
2.7. Apoptosis/necrosis assay
Apoptosis-mediated cell death of tumor cells induced by
PHBV nanoparticle formulations were analyzed by using
Hoechst–propidium iodide double-staining and Annexin
V–propidium iodide double-staining methods.
2.7.1. Hoechst–propidium iodide double staining
Saos-2 cells were seeded in 48-well cell culture plates
at a density of 1 × 104 cells/well in DMEM-F12 medium
supplemented with 10% fetal bovine serum and 1%
penicillin–streptomycin at 37 °C in a humidified 5% CO2
atmosphere. The cells were then treated with free etoposide,
nontargeted PHBV nanoparticles, and folic-acid–attached
PHBV nanoparticles (polymer/drug ratio; (1/1, 1/0.5,
1/0.25). Increasing concentrations (5, 10, 25, and 50 µg/
mL) of samples were incubated with the cells. Untreated
cells and blank nanoparticle-treated cells were used as
controls. Following 24 h of treatment, cells were collected
and washed with PBS. Cells were stained with Hoechst
33342 nucleic acid dye (2 µg/mL), propidium iodide (2 µg/
mL), and DNAse free-RNAse (100 µg/mL) for 15 min at
room temperature. The number of apoptotic and necrotic
cells were determined by inverted fluorescence microscope
(Leica DM6000, Leica Microsystems; Wetzlar, Germany).
The number of apoptotic and necrotic cells in 10 randomly
chosen microscopic fields were counted and the results
were expressed as a ratio of apoptotic and necrotic cells to
normal cells. The data are represented as means ± SD.
2.7.2. Annexin V–propidium iodide double staining
Saos-2 cells were treated with a medium containing free
etoposide, nontargeted PHBV nanoparticles, and folic-acid–
attached PHBV nanoparticles at increasing concentrations
(5, 10, 25, and 50 µg/mL) of samples. Nontreated cells were
used as the control. Following the treatment, adherent
cells were collected, washed in PBS, and resuspended in
binding buffer (10 mM HEPES/NaOH, pH: 7.4, 140 mM
NaCl, 2.5 mM CaCl2). Annexin V and propidium iodide
were added to a final concentration of 10 µg/mL and 1 µg/
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mL, respectively, and the cells were incubated in darkness
for 10 min. The number of Annexin V-labeled cells was
counted using an inverted fluorescence microscope (Leica
DM6000, Leica Microsystems). For each image (at least
100 cells/field) three randomly selected microscopic fields
were evaluated. The data are represented as means ± SD.
3. Results and discussion
3.1. Characterization of nanoparticles
3.1.1. Morphological characterization of nanoparticles
The morphological image of PHBV nanoparticles obtained
by SEM is shown in Figure 1. Obtained nanoparticles had
a spherical shape and were homogeneously distributed
with narrow size distribution.
3.1.2. FTIR analysis of folic-acid–conjugated PHBV
nanoparticles
The surface functionalization of PHBV nanoparticles was
confirmed by FTIR (Figure 2). As seen in Figure 2C, the
absorption bands at 3335 cm–1 and 1635 cm–1 correspond
to the NH– stretching and C=O stretching vibrations
of the –CONH2 group, indicating a coupling reaction
between the folic acid and the PHBV nanoparticle through
the amide linkage (Zhang et al., 2010). Additionally, the
folic-acid–conjugated PHBV had an adsorption peak at
1462 cm–1 assigned to the stretching vibrations of C=C in

Figure 1. SEM image of PHBV nanoparticles.

722

the backbone of the aromatic ring of folic acid (Xu et al.,
2016).
3.1.3. Particle size and zeta potential
The biological fate of nanoparticles and the interaction
of nanoparticles with cells depend on several key
parameters, including size, surface charge, cell type,
and the modification of the nanoparticles (Decuzzi and
Ferrari, 2007). These factors affect drug release rate,
pharmacokinetics and biodistribution of the nanoparticles,
cellular uptake, and therapeutic effect of encapsulated
drugs. Studies have demonstrated that the smaller size of
polymeric nanoparticles can reduce the reticuloendothelial
system clearance, prolonging the time of circulation
of nanoparticles in the bloodstream, thus resulting in
high intracellular uptake (van Engeland et al., 1998). In
this study, the nanoparticle size–size distribution had
been optimized by changing the polymer concentration,
homogenization rate, and emulsifier concentration.
The dispersed and continuous phase viscosities alter
the efﬁciency of particle size during the formation of
nanoparticles (Qian and McClements, 2011). The increase
in polymer concentration resulted in larger nanoparticle
size due to the increase in the viscosity of the polymer.
It can be postulated that the dispersion of the polymer
becomes difficult and this factor contributes to the larger
particle size (Table 1).

ALP et al. / Turk J Biol

Figure 2. FTIR spectra of (A) PHBV nanoparticle, (B) folic acid (pure), (C) folic-acid–conjugated PHBV
nanoparticle.
Table 1. Effect of polymer concentration, emulsifier concentration, and homogenization rate on particle size and
polydispersity index.
Sample
no.

PHBV/chloroform
(mg/mL)

Tween80/dH2O
(mL/mL)

Homogenization
rate (rpm)

Particle size
(nm ± SD)

Polydispersity
index (PDI)

1

0.5

0.05

24,000

210 ± 10

0.133

2

1

0.05

24,000

232 ± 8

0.165

3

2

0.05

24,000

430 ± 15

0.172

4

0.5

0.03

24,000

347 ± 15

0.169

5

0.5

0.01

24,000

650 ± 20

0.192

6

0.5

0.05

7000

622 ± 25

0.227

7

0.5

0.05

15,500

540 ± 20

0.215

The effect of homogenization rate on size and
size distribution was determined by using various
homogenization rates (7000–24000 rpm) and the

results obtained are shown in Table 1. The size of
nanoparticles decreased clearly with the increase in the
rate of homogenization, as confirmed by previous studies
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(Tcholakova et al., 2003; Tan and Nakajima, 2005). The
stirring speed is a key factor during the emulsification
stage to obtain smaller particle size due the high shear
force (Baena-Aristizabal et al., 2016).
Tween 80 acted as a stabilizer in the external aqueous
phase and the concentration of Tween 80 played an
important role in determining the size of the nanoparticles.
It caused a decrease in surface tension difference between
the organic and aqueous phases. As seen in Table 1, the
increase in emulsifier concentration significantly reduced
particle size. This trend was expected because an increased
amount of emulsifier caused a rapidly forming layer of
emulsifier molecules for the new particle surfaces formed
during homogenization process (Qian and McClements,
2011).
As a result of these optimization studies, optimum
drug-targeting–applicable nanoparticles were obtained
around 210 nm in diameter with a PdI of 0.133, confirmed
by dynamic light scattering measurement (Figure 1; Tables
1 and 2). This optimum formulation was used for ligandbinding, drug loading/release, cytotoxicity, and apoptosis/
necrosis studies.
Table 2 shows the size–size distribution and zeta
potential of the different formulations of PHBV
nanoparticles used for cytotoxicity and apoptosis/
necrosis studies. The size–size distribution of the prepared
nanoparticles was observed to be varied between 200
nm and 250 nm, depending on folic acid modification
and etoposide loading. PHBV nanoparticles exhibited a
negative surface charge in the range of –21 and –27 mV.
As shown in Table 2, the observed values confirm that the
zeta potentials of nanoparticles were not greatly affected
by increasing amount of etoposide content. For the

folic-acid–attached nanoparticles, no significant change
was found for the surface charge, despite the carboxylic
acid group of folic acid. The results are consistent with
other studies on folate-conjugated nanocarriers (Park et
al., 2005). The presence of a negative charge on PHBV
nanoparticles is a useful characteristic of nanoparticles
for improving targeting efficiency. This negative charge
reduces the protein-binding affinity of drug-loaded
nanoparticles, prolonging the duration at which they
remain in circulation without inducing an immune
response (Vilos et al., 2013). Patil et al. demonstrated that
the positively charged nanoparticles were found to adsorb
more bovine serum albumin, while nanoparticles with
negative zeta potential had less protein adsorption (Patil
et al., 2007).
3.2. Etoposide loading and release studies
With an increase in the initial feeding amount of etoposide
from 1/0.25 to 1/1, the encapsulation efficiency of PHBV
nanoparticles decreased from 34% to 27%. This result
can be explained by the enlarged concentration gradient
of drug between the nanoparticle and the outer aqueous
phase, which caused more drug loss in the nanoparticle
preparation procedure and, in turn, a decrease in
encapsulation efficiency of PHBV nanoparticles (Lu et al.,
2010). PHBV nanoparticles with an initial polymer/drug
ratio of 1/0.5 resulted in 29% encapsulation efficiency.
The drug release profile of nanoparticles loaded with
different amounts of drug is shown in Figure 3. The release
from a polymeric nanoparticle matrix system, in which the
drug is uniformly embedded, generally occurs through a
combination of diffusion and degradation of the matrix.
The initial drug burst dominates the early release phase,
followed by a slow fall in the release rate. The initial fast

Table 2. Data showing the size and zeta potentials of different formulations of nanoparticles.
Nanoparticles

Size (nm)

Polydispersity (PDI)

Zeta potential (mV)

PHBV-NPs

210 ± 10

0.133

–27.2

PHBV-Eto-NPsa

212 ± 15

0.145

–25.6

PHBV-Eto-NPs

214 ± 20

0.147

–25.2

217 ± 12

0.150

–24.9

219 ± 18

0.162

–23.7

FA-PHBV-Eto-NPsa

221 ± 20

0.166

–22.6

FA-PHBV-Eto-NPs

223 ± 24

0.169

–21.8

FA-PHBV-NPs

225 ± 30

0.174

–21.1

b

PHBV-Eto-NPs

c

FA-PHBV-NPs

b

c

1/0.25 PHBV/etoposide
1/0.5 PHBV/etoposide
c
1/1 PHBV/etoposide
a

b
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Figure 3. Effect of PHBV/etoposide ratio (w/w) on cumulative etoposide release over time.

drug release is due to the drug being located on or near
the particle surface, which diffuses faster to the media,
resulting in higher drug release, while a decline in the
extent of drug release can be explained by the fact that a
higher proportion of accumulation of etoposide within
particles restricts the diffusion of drug to the aqueous
phase (Bajpai and Mishra, 2005).
3.3. In vitro cytotoxicity studies
Blank PHBV nanoparticles had no significant cytotoxic
effect on Saos-2 cells, indicating the safety of the prepared
nanoparticles for human use. The viability of Saos-2 cells
decreased with the increase in drug concentration of
nontargeted nanoparticles and incubation time. After 24
h incubation, 23.6 ± 10.7%, 22.1 ± 10.0%, and 16.3 ± 8.8.%
cell mortality was observed for 50 µg/mL of nontargeted
nanoparticles at 1/1, 1/0.5, and 1/0.25 initial polymer/drug
ratios, respectively. After 48 h incubation, 37.7 ± 8.6%, 26.2
± 9.0%, and 28.5 ± 9.2% cell mortality was observed for
50 µg/mL of nontargeted nanoparticles at 1/1, 1/0.5, and
1/0.25 initial polymer/drug ratios, respectively (Figures
4A and 4B).
The toxicity of folic-acid–conjugated nanoparticles
was also significantly higher than that of nontargeted
nanoparticles. Moreover, cell viability decreased with
the increase in drug concentration as well as incubation
time for targeted nanoparticles (Figures 4A and 4B). For
24 h incubation, folic-acid–conjugated 50 µg/mL PHBV

nanoparticles at 1/1, 1/0.5, and 1/0.25 initial polymer/drug
ratios resulted in 37.8 ± 6.1%, 23.2 ± 10.01%, and 19.7 ±
5.4% cell mortality, respectively. After 48 h incubation,
folic-acid–conjugated 50 µg/mL PHBV nanoparticles at
1/1, 1/0.5, and 1/0.25 initial polymer/drug ratios caused
43.2 ± 4.3%, 38.5 ± 9.8%, and 35.9 ± 5.6% cell mortality,
respectively. The overexpression of folate receptors on
the surface of Saos-2 cells may significantly enhance the
uptake of the targeted nanoparticles via folate-receptor–
mediated endocytosis and therefore targeted nanoparticles
cause higher cytotoxicity than nontargeted nanoparticles
(Yang et al., 2007).
Free etoposide at various concentrations (5–50 µg/mL)
was also tested by MTT assay on Saos-2 cells. Higher drug
concentrations and incubation times caused lower cell
viability. However, a nonsignificant decrease in mortality
was observed (Figure 4C).
The results revealed that all the nanoparticle
formulations exhibited typical time-dependent and
concentration-dependent
cytotoxicity.
Cytotoxicity
was also observed to be highly affected by folic acid
conjugation. The results obtained from the in vitro
cytotoxicity assay confirmed the enhanced efficacy and
higher cytotoxic effect of etoposide loaded and targeted
PHBV nanoparticles as compared with etoposide-loaded
and nontargeted PHBV nanoparticles, as well as pure
etoposide.
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Figure 4. Cytotoxicities of different formulations of PHBV nanoparticles inoculated to Saos-2 cells for (A) 24 h and (B) 48 h. (C)
Cytotoxicity of pure etoposide on Saos-2 cells for 24 h and 48 h.

3.4. Apoptosis/necrosis assay
The apoptogenic properties of nanoparticle formulations
were investigated through morphological changes in saos-
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2 cells. Cell shrinkage, membrane blebbing, chromatin
cleavage, nuclear condensation, and formation of pyknotic
bodies of condensed chromatin are the typical common

ALP et al. / Turk J Biol
features of apoptotic cells (Moongkarndi et al., 2004).
In the present study, apoptosis was assayed cytologically
using the double-staining methods of Hoechst–propidium
iodide and Annexin V–propidium iodide. Morphological
changes in cell nuclei were observed by inverted
fluorescence microscope. The percentages of apoptotic
and necrotic cells were also determined.
The blue fluorescent Hoechst 33342 nucleic acid stain
is a cell permeable dye usually used to identify chromatin
condensation and fragmentation by staining the
condensed pyknotic nuclei in apoptotic cells. Propidium
iodide is a DNA-binding dye that can only stain cells with
increased plasma membrane permeability and loss of
plasma membrane integrity. In late apoptotic and necrotic
cells, the integrity of the plasma and nuclear membranes
decreases, allowing propidium iodide to pass through
the membranes and display red fluorescence. Apoptosis
is accompanied by a change in plasma membrane
structure by surface exposure of phosphatidylserine.
Translocation, and in turn apoptosis, can be detected by
its affinity for Annexin V, a phospholipid-binding protein
(van Engeland et al., 1998). Therefore, using Annexin V
in combination with propidium iodide detects apoptotic
cells and discriminates between apoptosis and necrosis.
The percentages of apoptotic cells (apoptotic index)
obtained by Hoechst–propidium iodide and Annexin
V–propidium iodide staining methods were obtained in
parallel and are given in Table 3. Microscopic analysis of
apoptotic cells under inverted fluorescent microscope
is shown in Figures 5–7. Apoptotic cell photographs
obtained from double staining with Hoechst 33342
and propidium iodide are shown in Figure 5. The
morphological observation in the cell nuclei of Saos2 cells after treatment with tested compounds showed
significant morphological alterations when compared

to the control. As observed in Figure 5A, untreated cells
exhibited no difference in cell nuclei, with a less bright
blue fluorescence due to Hoechst dye. On the other hand,
cells treated with etoposide, untargeted etoposide-loaded
nanoparticles, and folic-acid–conjugated etoposideloaded nanoparticles exhibited decomposed nuclei and
were brighter blue compared to untreated cells (Figures
5B–5D).
As seen in Table 3, apoptotic effect was low at low
concentrations of etoposide. However, apoptotic effect
increased with higher drug concentrations. The same
result was also observed for drug-loaded nanoparticles as
well as drug-loaded nanoparticles targeted by folic acid.
A significant increase in cell apoptosis was observed in
cells treated with folic-acid–conjugated, etoposide-loaded
PHBV nanoparticles compared to free drug, suggesting
that folic acid conjugation facilitated the incorporation
of etoposide into Saos-2 cells. The highest percentage
of apoptosis was obtained in cells treated with targeted
nanoparticles having a 1/1 polymer/drug ratio. According
to the results, the apoptotic index rose by 1%–2% when
etoposide was loaded into PHBV nanoparticles. When
folic acid was conjugated to drug-loaded nanoparticles,
the apoptotic effect increased by 10 ± 2% with respect to
the drug alone and by 8 ± 2% with respect to nontargeted
drug-loaded nanoparticles. Figures 6A, 6C, and 6E reveal
little green coloring caused by Annexin V staining on the
cell membrane, since there was low apoptosis for the cells
treated with untargeted etoposide-loaded nanoparticles,
while Figures 7A, 7C, and 7E show green coloring on
cell membrane due to the reaction formed by Annexin V.
Moreover, in Figure 7E, the effect of folic-acid–targeted
particles carrying the drug in a ratio of 1/1 (50 µg/mL) and
the increase in the number of cell membranes stained in
green is clearly seen.

Table 3. Apoptotic (AI) and necrotic percentage indices (NI) of etoposide (Eto), nanoparticles loaded with different ratios of etoposide
(PHBV-Eto), and folic-acid–targeted nanoparticles loaded with different ratios of etoposide (FA/PHBV-Eto) in an osteocarcinoma cell
line. Data represent means ± SD.

Formulations

Sample amount (µg/mL)

AI (%)

NI (%)

0

5

10

25

50

0

5

10

25

50

Etoposide

1±1

2±1

6±1

9±2

14 ± 1

1±1

4±1

8±1

12 ± 2

17 ± 3

Etoposide/PHBV (1:0.25)

1±1

2±1

4±1

6±1

8±1

2±1

3±1

5±1

12 ± 1

17 ± 1

FA-Eto/PHBV (1:0.25)

1±1

2±1

6±1

8±2

13 ± 1

1±1

1±1

7±1

14 ± 2

21 ± 2

Eto/PHBV (1:0.5)

1±1

5±1

8±1

12 ± 1

15 ± 1

1±1

3±1

9±1

11 ± 1

15 ± 2

FA-Eto/PHBV (1:0.5)

2±1

8±1

12 ± 1

18 ± 2

21 ± 2

2±1

5±1

13 ± 2

16 ± 2

20 ± 1

Eto/PHBV (1:1)

2±1

4±1

7±1

13 ± 2

15 ± 1

2±1

3±1

6±1

12 ± 2

18 ± 1

FA-Eto/PHBV (1:1)

1±1

8±1

13 ± 1

17 ± 1

24 ± 2

1±1

8±1

11 ± 1

19 ± 1

25 ± 2
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Figure 5. Apoptotic cell fluorescent photographs obtained from the Hoechst 33342/propidium iodide staining. Osteosarcoma cells (A)
stained by Hoechst 33342 and not treated with drug and nanoparticles (control group), (B) interacted with NP (50 µg/mL) loaded with
etoposide in the ratio of 1/0.25, (C) interacted only with etoposide (50 µg/mL), and (D) interacted with folic-acid–targeted NP (50 µg/
mL) loaded with etoposide at a ratio of 1/1.

In our study, necrotic index was examined under
fluorescent light (by FITC filter) at a wavelength of 480–
520 nm, and at this wavelength necrotic cell nuclei were
observed to be red. Healthy cells were not stained by
propidium iodide and apoptotic cells were observed to be
green at simultaneous times. Photographs of necrotic cells
are given in Figure 8 and necrotic percentage indices are
given in Table 3. As seen in Table 3, higher concentrations
of the drug resulted in an increase in toxicity, and
therefore, an increase in necrosis. The necrotic effect of
targeted drug-loaded nanoparticles (Figures 8C and E) was
found to be 8 ± 1% higher compared to cells treated with
drug alone and 4 ± 1% higher compared to nontargeted
drug-loaded nanoparticles. The highest necrotic index
of approximately 25 ± 1% was obtained in nanoparticles
targeted with folic acid at the 1/1 polymer/drug ratio and
50 µg/mL nanoparticle concentration (Figures 8E and 8F).
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In conclusion, a targeted drug delivery system
composed of PHBV/etoposide was successfully prepared
for the treatment of osteosarcoma. The surface of
nanoparticles was conjugated with folic acid to enhance
the etoposide delivery to tumor cells. The nanoparticles
were nanosized between 200 nm and 250 nm, depending
on polymer/drug ratio and folic acid conjugation. The
in vitro drug release profiles of nanoparticles exhibited a
biphasic pattern, with an initial fast release followed by a
slower release. Encapsulation efficiencies of nanoparticles
were between 27% and 34%, depending on initial
polymer/drug concentration. These characteristics,
along with targeting ligand conjugation, facilitated
the cellular uptake of prepared nanoparticles in Saos2 cells. Increased cellular uptake led to the improved
cytotoxic effect of targeted nanoparticles in comparison
to free etoposide and nontargeted etoposide-loaded

ALP et al. / Turk J Biol

Figure 6. Apoptotic cell fluorescent photographs obtained from the Annexin V/propidium iodide staining. (A) Osteocarcinoma cells
treated with untargeted nanoparticles at a polymer/drug ratio of 1/0.25 (50 µg/mL). (B) UV–Vis photo of same field. (C) Osteocarcinoma
cells treated with untargeted nanoparticles at the polymer/drug ratio of 1/0.5 (50 µg/mL). (D) UV–Vis photo of same field. (E)
Osteocarcinoma cells treated with untargeted nanoparticles at a polymer/drug ratio of 1/1 (50 µg/mL), (F) UV–Vis photo of same field.
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Figure 7. Apoptotic cell fluorescent photographs obtained from the Annexin V/propidium iodide staining. (A) Osteocarcinoma cells
stained interacted with folic-acid–targeted NP loaded with etoposide (50 µg/mL) in a polymer/drug ratio of 1/0.25. (B) UV–Vis photo
of same field. (C) Osteocarcinoma cells interacted with folic-acid–targeted NP loaded with etoposide (50 µg/mL) at a polymer/drug
ratio of 1/0.5. (D) UV–Vis photo of same field. (E) Osteocarcinoma cells interacted with folic-acid–targeted NP loaded with etoposide
(50 µg/mL) at a polymer/drug ratio of 1/1. (F) UV–Vis photo of same field.
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Figure 8. Necrotic cell photographs obtained from Annexin V staining performed using propidium iodide. (A) Osteocarcinoma cells
stained by Annexin V staining method and not treated with drug and nanoparticles (control group). (B) Osteocarcinoma cells interacted
with folic acid targeted NP loaded with etoposide (50 µg/mL) at a polymer/drug ratio of 1/1. (C) Osteocarcinoma cells interacted with
folic-acid–targeted NP loaded with etoposide (50 µg/mL) at a polymer/drug ratio of 1/0.5. (D) UV–Vis photo of same field; necrotic
cell nuclei look red and nonnecrotic cell nuclei look colorless. (E) Osteocarcinoma cells interacted with folic-acid–targeted NP loaded
with etoposide (50 µg/mL) at a polymer/drug ratio of 1/1. (F) UV–Vis photo of same field.
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nanoparticles, which is also in agreement with apoptosis/
necrosis studies. These findings suggest that folic-acid–
conjugated PHBV nanoparticles have potential for use as
a targeted formulation of etoposide for the treatment of
osteosarcoma. Further in vivo studies have been planned
to demonstrate the efficacy of these nanoparticles as a
targeted drug delivery system.
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